name	nt_name	aa_name	multi_aa_name	multiaa_comb_mutation	start	vcf_gene	chrom_region	mutation_type	sequence_depth	sample_size	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao	reference_seq	variant_seq	viral_lineages	function_category	citation	comb_mutation	function_description	heterozygosity	clade_defining	who_variant	status	voi_designation_date	voc_designation_date	vum_designation_date
c.-12_-11insAACA	c.-12_-11insAACA				28262	N	intergenic		100	100						0	100	G	GAACA	P.1					False	True	Gamma	VOC		11-Jan-2021	
c.C-25T	c.C-25T				241	orf1ab	5' UTR		100	100						0	100	C	T	P.1					False	True	Gamma	VOC		11-Jan-2021	
c.G29764A	c.G*4380A				29764	intergenic	Stem-loop,3' UTR		100	100						87	13	G	A	P.1					False	False	Gamma	VOC		11-Jan-2021	
p.3676del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'S3675del', 'F3677del'	11287	orf1ab	ORF1ab		200	100			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	200	GTCTGGTTTT	G	P.1, P.1					False	True, True	Gamma	VOC		11-Jan-2021	
p.A35A	c.G105T	p.A35A			28378	N	N	SILENT	100	100						72	28	G	T	P.1					False	False	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.32x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	anthropozoonotic events	Montagutelli et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	antibody epitope effects	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	antibody epitope effects	Dejnirattisai et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S'	"The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (~wild type), with only 64% neutralization at 10 μg/mL.  Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed.  Given that there is likely a single supersite (""i"") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primaruly anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with  neutralization of Victoria (~wild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1,  with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a  greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351."	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	antibody epitope effects	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G'	1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	convalescent plasma escape	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	convalescent plasma escape	Luftig et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	convalescent plasma escape	McCallum et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	convalescent plasma escape	Mendes-Correa et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	convalescent plasma escape	Tang et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	convalescent plasma escape	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	pharmaceutical effectiveness	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	reinfection	Malta Romano et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	trafficking	Esclera et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	trafficking	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	transmissibility	Stefanelli et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y'	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Alenquer et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Andrade et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Choi et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Gallagher et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Gong et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Hitchlings et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Leier et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Tarke et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G'	1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	virion structure	Spratt et al. (2021)		Estimated free energy change (ddG) for this variant is 0.43 kcal/mol (i.e. stabilizing relative to wild type) 	False	True	Gamma	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	100	100						0	100	G	T	P.1	virion structure	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	True	Gamma	VOC		11-Jan-2021	
p.D156D	c.T468C	p.D156D			733	orf1ab	ORF1ab	SILENT	100	100			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	0	100	T	C	P.1					False	True	Gamma	VOC		11-Jan-2021	
p.D4532D	c.C13596T	p.D4532D			13860	orf1ab	ORF1ab	SILENT	100	100			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	100	C	T	P.1					False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	ACE2 receptor binding affinity	Dejnirattisai et al. (2021)	'K417T', 'E484K', 'N501Y'	The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with ~19x greater affinity that wild type.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D138Y'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.32x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'E484K'	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'H655Y'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'K417T'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.28x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'L18F'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.07x decrease in binding (KD) relative to D614G. Compare to increased binding in full Spike variant complements for major lineages containing this variant subset: 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'N501Y'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma)."	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'P26S'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.58x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'R190S'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.82x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.69x decrease in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'T20N'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.96x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	ACE2 receptor binding affinity	Li et al. (2020)		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	anthropozoonotic events	Montagutelli et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	antibody epitope effects	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	antibody epitope effects	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	convalescent plasma binding	Gong et al. (2021)	'D138Y'	1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	convalescent plasma binding	Gong et al. (2021)	'E484K'	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	convalescent plasma binding	Gong et al. (2021)	'H655Y'	1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	convalescent plasma binding	Gong et al. (2021)	'K417T'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	convalescent plasma binding	Gong et al. (2021)	'L18F'	1.66x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. Compare to decreased binding in full Spike variant complements for major lineages containing this variant subset: 0.96x (B.1.351 aka Beta), 0.77x (P.1 aka Gamma).	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	convalescent plasma binding	Gong et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	convalescent plasma binding	Gong et al. (2021)	'N501Y'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	convalescent plasma binding	Gong et al. (2021)	'P26S'	1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	convalescent plasma binding	Gong et al. (2021)	'R190S'	1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	convalescent plasma binding	Gong et al. (2021)	'T1027I'	1.56x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	convalescent plasma binding	Gong et al. (2021)	'T20N'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	convalescent plasma escape	Tada et al. (2021)	'E484K'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	convalescent plasma escape	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	immunosuppression variant emergence	Landis et al. (2021)		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	reinfection	Malta Romano et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	syncytium formation	Kim et al. (2021)		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	syncytium formation	Kim et al. (2021)	'E484K', 'N501Y'	~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	syncytium formation	Kim et al. (2021)	'N501Y'	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	tissue specific neutralization	Planas et al. (2021)		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	trafficking	Barrett et al. (2021)		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	trafficking	Daniloski et al. (2021)		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	trafficking	Esclera et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	trafficking	Kim et al. (2021)		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	trafficking	Kim et al. (2021)		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	trafficking	Kim et al. (2021)	'E484K', 'N501Y'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	trafficking	Kim et al. (2021)	'E484K', 'N501Y'	~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	trafficking	Kim et al. (2021)	'N501Y'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	trafficking	Kim et al. (2021)	'N501Y'	~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	trafficking	Kuzmina et al. (2021)	'E484K'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	trafficking	Kuzmina et al. (2021)	'E484K', 'N501Y'	~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	200	100						0	200	A	G	P.1, P.1	trafficking	Kuzmina et al. (2021)	'N501Y'	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	True, True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	trafficking	Ozono et al. (2020)		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	trafficking	Zhang et l. (2020)		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	transmissibility	Stefanelli et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y'	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccine neutralization efficacy	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccine neutralization efficacy	Gallagher et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	'E484K', 'V1176F'	Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose)  and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccine neutralization efficacy	Kuzmina et al. (2021)		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccine neutralization efficacy	Kuzmina et al. (2021)	'E484K'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccine neutralization efficacy	Kuzmina et al. (2021)	'E484K', 'N501Y'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccine neutralization efficacy	Kuzmina et al. (2021)	'N501Y'	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccine neutralization efficacy	Leier et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccine neutralization efficacy	Tada et al. (2021)	'E484K'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccine neutralization efficacy	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccinee plasma binding	Gong et al. (2021)	'D138Y'	1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccinee plasma binding	Gong et al. (2021)	'E484K'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccinee plasma binding	Gong et al. (2021)	'H655Y'	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccinee plasma binding	Gong et al. (2021)	'K417T'	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccinee plasma binding	Gong et al. (2021)	'L18F'	1.30x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.28x increase (B.1.351 aka Beta), and 1.14x decrease (P.1 aka Gamma). 1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.17x increase (B.1.351 aka Beta), and 1.47x decrease (P.1 aka Gamma).	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccinee plasma binding	Gong et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccinee plasma binding	Gong et al. (2021)	'N501Y'	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccinee plasma binding	Gong et al. (2021)	'P26S'	1.23x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccinee plasma binding	Gong et al. (2021)	'R190S'	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.59x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccinee plasma binding	Gong et al. (2021)	'T1027I'	1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	vaccinee plasma binding	Gong et al. (2021)	'T20N'	1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.39x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	viral load	Plante et al. (2020)		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	virion structure	Spratt et al. (2021)		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	virion structure	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	virion structure	Weissman et al. (2020)		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	virion structure	Yurkovetskiy et al. (2020)		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	True	Gamma	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	100	100						0	100	A	G	P.1	virion structure	Zhang et al. (2020)		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	True	Gamma	VOC		11-Jan-2021	
p.D828D	c.C2484T	p.D828D			2749	orf1ab	ORF1ab	SILENT	100	100			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	100	C	T	P.1					False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	ACE2 receptor binding affinity	Barton et al. (2021)	'K417T', 'N501Y'	The affinity of the P.1 RBD variants for ACE2 increased by 5.3 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. 	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	ACE2 receptor binding affinity	Barton et al. (2021)	'N501Y'	In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	ACE2 receptor binding affinity	Collier et al. (2021)		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	ACE2 receptor binding affinity	Dejnirattisai et al. (2021)	'K417T', 'N501Y', 'D614G'	The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with ~19x greater affinity that wild type.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G'	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	ACE2 receptor binding affinity	Laffeber et al. (2021)		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	ACE2 receptor binding affinity	Liu et al. (2021)		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	ACE2 receptor binding affinity	Ramanathan et al. (2021)		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	ACE2 receptor binding affinity	Starr et al. (2020)		Experimentally, ACE2 binding affinity increased 0.06 fold	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	ACE2 receptor binding affinity	Tian et al. (2021)		Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	ACE2 receptor binding affinity	Tian et al. (2021)		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	ACE2 receptor binding affinity	Vogel et al. (2021)		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	ACE2 receptor binding affinity	Zahradnik et al. (2021)		Among the first selected variants in an in vitro evolution experiment for ACE2 binding.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	T cell evasion	Reynolds et al. (2021)		Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	anthropozoonotic events	Montagutelli et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	antibody epitope effects	Chen et al. (2021)		Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	antibody epitope effects	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	antibody epitope effects	Chen et al. (2021)	'N501Y'	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	antibody epitope effects	Collier et al. (2021)		Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	antibody epitope effects	Gaebler et al. (2021)		Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	antibody epitope effects	Li et al. (2021)		Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	antibody epitope effects	Liu et al. (2020)		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	antibody epitope effects	Rappazzo et al. (2021)		Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	antibody epitope effects	Sun et al. (2021)		Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	antibody epitope effects	Wang et al. (2021)		Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus)	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	antibody epitope effects	Wang et al. (2021)		Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	antibody epitope effects	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G'	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Alenquer et al. (2021)		Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Andreano et al. (2020)		This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Cele et al. (2021)		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Chen et al. (2021)	'N501Y'	In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples. 	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Liu et al. (2021)		Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Luftig et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	McCallum et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Mendes-Correa et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Schmidt et al. (2021)		Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Tada et al. (2021)		The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees)	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Tada et al. (2021)	'D614G'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Tang et al. (2021)		As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Tang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Wang et al. (2021)		The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Wibmer et al. (2021)		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Wibmer et al. (2021)		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	convalescent plasma escape	Zhou et al. (2021)		"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera."	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	monoclonal antibody serial passage escape	Barnes et al. (2020)		The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	monoclonal antibody serial passage escape	Baum et al. (2020)		Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	monoclonal antibody serial passage escape	Greaney et al. (2020)		Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	monoclonal antibody serial passage escape	Starr et al. (2021)		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	monoclonal antibody serial passage escape	Wang et al. (2021)		Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	monoclonal antibody serial passage escape	Weisblum et al. (2020)		Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	outcome hazard ratio	Funk et al. (2021)	'L18F', 'K417T', 'N501Y', 'H655Y'	On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	outcome hazard ratio	Ribas Freitas et al. (2021)	'L18F', 'K417T', 'N501Y', 'H655Y'	In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI 	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	outcome hazard ratio	Santos de Oliviera et al. (2021)	'L18F', 'K417T', 'N501Y', 'H655Y'	In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged  30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably,  the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases.  Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after  identification of a novel SARS-CoV-2 strain circulating in Brazil.  [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to  February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence]	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	pharmaceutical effectiveness	Engelhart et al. (2021)		Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	pharmaceutical effectiveness	Engelhart et al. (2021)		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	pharmaceutical effectiveness	Engelhart et al. (2021)	'K417T', 'N501Y'	Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from P.1.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	pharmaceutical effectiveness	Engelhart et al. (2021)	'N501Y'	Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	pharmaceutical effectiveness	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	pharmaceutical effectiveness	Liu et al. (2021)		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	reinfection	Malta Romano et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	syncytium formation	Kim et al. (2021)	'N501Y', 'D614G'	~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	trafficking	Esclera et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	trafficking	Ferriera et al (2021)		This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. 	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	trafficking	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	trafficking	Kim et al. (2021)	'N501Y', 'D614G'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	trafficking	Kim et al. (2021)	'N501Y', 'D614G'	~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	trafficking	Kuzmina et al. (2021)	'D614G'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	trafficking	Kuzmina et al. (2021)	'N501Y', 'D614G'	~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	trafficking	Tada et al. (2021)		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	transmissibility	Stefanelli et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'N501Y', 'D614G', 'H655Y'	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Alenquer et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Andrade et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Chen et al. (2021)	'N501Y'	The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Choi et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Ferreira et al. (2021)		Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Gallagher et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	'D614G', 'V1176F'	Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose)  and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Gong et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Hitchlings et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Ikegame et al. (2021)		E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Jangra et al. (2021)		Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain. 	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Kuzmina et al. (2021)	'D614G'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Kuzmina et al. (2021)	'N501Y', 'D614G'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Leier et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Solfrosi et al. (2021)		Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test). 	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Tada et al. (2021)	'D614G'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Tarke et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Wang et al. (2021)		In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccine neutralization efficacy	Xie et al. (2021)	'N501Y'	In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	virion structure	Spratt et al. (2021)		Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type) 	False	True	Gamma	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	100	100						0	100	G	A	P.1	virion structure	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	True	Gamma	VOC		11-Jan-2021	
p.E5665D	c.G16995T	p.E5665D			17259	orf1ab	ORF1ab	MISSENSE	100	100			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	0	100	G	T	P.1					False	True	Gamma	VOC		11-Jan-2021	
p.E92K	c.G274A	p.E92K			28167	ORF8	ORF8	MISSENSE	100	100						0	100	G	A	P.1					False	True	Gamma	VOC		11-Jan-2021	
p.F3677del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'S3675del', '3676del'	11287	orf1ab	ORF1ab		100	100			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	100	GTCTGGTTTT	G	P.1					False	True	Gamma	VOC		11-Jan-2021	
p.F924F	c.C2772T	p.F924F			3037	orf1ab	ORF1ab	SILENT	100	100			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	100	C	T	P.1					False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	anthropozoonotic events	Esclera et al. (2021)		Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	anthropozoonotic events	Montagutelli et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	antibody epitope effects	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	antibody epitope effects	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G'	1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Luftig et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	McCallum et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Mendes-Correa et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Tang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	homoplasy	Borges et al. (2021)		In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent. 	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	outcome hazard ratio	Funk et al. (2021)	'L18F', 'K417T', 'E484K', 'N501Y'	On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	outcome hazard ratio	Ribas Freitas et al. (2021)	'L18F', 'K417T', 'E484K', 'N501Y'	In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI 	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	outcome hazard ratio	Santos de Oliviera et al. (2021)	'L18F', 'K417T', 'E484K', 'N501Y'	In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged  30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably,  the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases.  Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after  identification of a novel SARS-CoV-2 strain circulating in Brazil.  [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to  February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence]	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	pharmaceutical effectiveness	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	reinfection	Malta Romano et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	trafficking	Esclera et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	trafficking	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	transmissibility	Stefanelli et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G'	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Alenquer et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Andrade et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Choi et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Gallagher et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Gong et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Hitchlings et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Leier et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Tarke et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G'	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	virion structure	Spratt et al. (2021)		Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type) 	False	True	Gamma	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	100	100						0	100	C	T	P.1	virion structure	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	True	Gamma	VOC		11-Jan-2021	
p.K1795Q	c.A5383C	p.K1795Q			5648	orf1ab	ORF1ab	MISSENSE	100	100			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	100	A	C	P.1					False	True	Gamma	VOC		11-Jan-2021	
p.K378N	c.G1134T	p.K378N			22696	S	S	MISSENSE	100	100						88	12	G	T	P.1	monoclonal antibody serial passage escape	Greaney et al. (2020)		Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody	False	False	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	ACE2 receptor binding affinity	Barton et al. (2021)		The K417T mutation decreased the affinity ~2 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	ACE2 receptor binding affinity	Barton et al. (2021)	'E484K', 'N501Y'	The affinity of the P.1 RBD variants for ACE2 increased by 5.3 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. 	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	ACE2 receptor binding affinity	Dejnirattisai et al. (2021)	'E484K', 'N501Y', 'D614G'	The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with ~19x greater affinity that wild type.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.28x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	anthropozoonotic events	Montagutelli et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	antibody epitope effects	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	antibody epitope effects	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	convalescent plasma escape	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	convalescent plasma escape	Luftig et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	convalescent plasma escape	McCallum et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	convalescent plasma escape	Mendes-Correa et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	convalescent plasma escape	Tang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	convalescent plasma escape	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	gene expression increase	Starr et al. (2020)		Experimentally, Spike gene expression increased 0.25 fold	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	monoclonal antibody serial passage escape	Starr et al. (2021)		Escape mutation against monoclonal antibody LY-CoV016	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	monoclonal antibody serial passage escape	Wang et al. (2021)		In vitro selection against class 1 antibody C682	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	outcome hazard ratio	Funk et al. (2021)	'L18F', 'E484K', 'N501Y', 'H655Y'	On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	outcome hazard ratio	Ribas Freitas et al. (2021)	'L18F', 'E484K', 'N501Y', 'H655Y'	In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI 	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	outcome hazard ratio	Santos de Oliviera et al. (2021)	'L18F', 'E484K', 'N501Y', 'H655Y'	In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged  30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably,  the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases.  Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after  identification of a novel SARS-CoV-2 strain circulating in Brazil.  [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to  February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence]	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	pharmaceutical effectiveness	Engelhart et al. (2021)		COR-101 lost ~16x binding against this isolated mutation. Estesevimab lost ~16x binding against this isolated mutation. m396 lost ~8x binding against this isolated mutation.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	pharmaceutical effectiveness	Engelhart et al. (2021)	'E484K', 'N501Y'	Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from P.1.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	pharmaceutical effectiveness	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	reinfection	Malta Romano et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	trafficking	Esclera et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	trafficking	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	vaccine neutralization efficacy	Alenquer et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	vaccine neutralization efficacy	Andrade et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	vaccine neutralization efficacy	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	vaccine neutralization efficacy	Choi et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	vaccine neutralization efficacy	Gallagher et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	vaccine neutralization efficacy	Gong et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	vaccine neutralization efficacy	Hitchlings et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	vaccine neutralization efficacy	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	vaccine neutralization efficacy	Leier et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	vaccine neutralization efficacy	Tarke et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	vaccine neutralization efficacy	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G'	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	virion structure	Spratt et al. (2021)		Estimated free energy change (ddG) for this variant is -0.64 kcal/mol (i.e. destabilizing relative to wild type) 	False	True	Gamma	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	100	100						0	100	A	C	P.1	virion structure	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.07x decrease in binding (KD) relative to D614G. Compare to increased binding in full Spike variant complements for major lineages containing this variant subset: 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	anthropozoonotic events	Montagutelli et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	antibody epitope effects	Chen et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	antibody epitope effects	Dejnirattisai et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S'	"The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (~wild type), with only 64% neutralization at 10 μg/mL.  Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed.  Given that there is likely a single supersite (""i"") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primaruly anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with  neutralization of Victoria (~wild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1,  with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a  greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351."	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	antibody epitope effects	McCallum et al. (2021)		"Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but no effect on other mAbs within that supersite"	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	antibody epitope effects	Wang et al. (2021)		Ablates neutralization by N-terminal-domain-targeting mAbs 4-19. Impairs neutralization by N-terminal-domain-targeting mAbs 4A8 and 2-17.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	antibody epitope effects	Wang et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G'	1.66x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. Compare to decreased binding in full Spike variant complements for major lineages containing this variant subset: 0.96x (B.1.351 aka Beta), 0.77x (P.1 aka Gamma).	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Cele et al. (2021)		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Chen et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Chen et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Hoffman et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Luftig et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	McCallum et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Mendes-Correa et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Tang et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Wang et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Wibmer et al. (2021)		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	outcome hazard ratio	Funk et al. (2021)	'K417T', 'E484K', 'N501Y', 'H655Y'	On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	outcome hazard ratio	Ribas Freitas et al. (2021)	'K417T', 'E484K', 'N501Y', 'H655Y'	In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI 	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	outcome hazard ratio	Santos de Oliviera et al. (2021)	'K417T', 'E484K', 'N501Y', 'H655Y'	In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged  30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably,  the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases.  Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after  identification of a novel SARS-CoV-2 strain circulating in Brazil.  [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to  February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence]	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	pharmaceutical effectiveness	Hoffman et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	reinfection	Malta Romano et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	trafficking	Esclera et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	trafficking	Hoffman et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	trafficking	Tada et al. (2021)		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggetsing that this  mutation does not contributing to cell entry fitness.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	transmissibility	Stefanelli et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y'	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Alenquer et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Andrade et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Chen et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Choi et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Gallagher et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Gong et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Hitchlings et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Hoffman et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Leier et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Tarke et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Wang et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G'	1.30x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.28x increase (B.1.351 aka Beta), and 1.14x decrease (P.1 aka Gamma). 1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.17x increase (B.1.351 aka Beta), and 1.47x decrease (P.1 aka Gamma).	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	100	100						0	100	C	T	P.1	virion structure	Wang et al. (2021)	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Barton et al. (2021)		The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance. 	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Barton et al. (2021)	'E484K'	In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Barton et al. (2021)	'K417T', 'E484K'	The affinity of the P.1 RBD variants for ACE2 increased by 5.3 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. 	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Collier et al. (2021)		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Dejnirattisai et al. (2021)	'K417T', 'E484K', 'D614G'	The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with ~19x greater affinity that wild type.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Gamez et al. (2021)		The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma)."	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Laffeber et al. (2021)		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Liu et al. (2021)		Reported 10-fold increase in ACE2 binding vs wildtype (Kd 	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Liu et al. (2021)		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Motozono et al. (2021)		~4-fold increase in binding affinity vs wild type.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Ramanathan et al. (2021)		Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Ramanathan et al. (2021)		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Santos and Passos (2021)		In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Starr et al. (2020)		Experimentally, ACE2 binding affinity increased 0.24 fold	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Tada et al. (2021)		This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. 	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Tian et al. (2021)		Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Tian et al. (2021)		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Vogel et al. (2021)		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Zahradnik et al. (2021)		Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd 	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	ACE2 receptor binding affinity	Zhu et al. (2021)		N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	T cell evasion	Reynolds et al. (2021)		Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p 	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	anthropozoonotic events	Montagutelli et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	antibody epitope effects	Chen et al. (2021)		Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	antibody epitope effects	Chen et al. (2021)	'E484K'	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	antibody epitope effects	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	antibody epitope effects	Collier et al. (2021)		Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	antibody epitope effects	Haynes et al. (2021)		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	antibody epitope effects	Klegerman et al. (2021)		Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	antibody epitope effects	Rees-Spear et al. (2021)		Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	antibody epitope effects	Shen et al. (2021)		Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x)	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	antibody epitope effects	Wang et al. (2021)		4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	antibody epitope effects	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma escape	Cele et al. (2021)		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma escape	Chen et al. (2021)	'E484K'	In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples. 	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma escape	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma escape	Kuzmina et al. (2021)		0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. 	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma escape	Luftig et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma escape	McCallum et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma escape	Mendes-Correa et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma escape	Rathnasinghe et al. (2021)		In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma escape	Shen et al. (2021)		Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma escape	Tada et al. (2021)		Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma escape	Tang et al. (2021)		As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma escape	Tang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma escape	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma escape	Wibmer et al. (2021)		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	convalescent plasma escape	Wibmer et al. (2021)		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	environmental condition stability	Tada et al. (2021)		Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	homoplasy	Flores-Alanis et al. (2021)		Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	immunosuppression variant emergence	Choi et al. (2020)		Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	monoclonal antibody serial passage escape	Wang et al. (2021)		In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	outcome hazard ratio	Funk et al. (2021)	'L18F', 'K417T', 'E484K', 'H655Y'	On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	outcome hazard ratio	Ribas Freitas et al. (2021)	'L18F', 'K417T', 'E484K', 'H655Y'	In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI 	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	outcome hazard ratio	Santos de Oliviera et al. (2021)	'L18F', 'K417T', 'E484K', 'H655Y'	In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged  30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably,  the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases.  Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after  identification of a novel SARS-CoV-2 strain circulating in Brazil.  [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to  February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence]	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	pharmaceutical effectiveness	Engelhart et al. (2021)		COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	pharmaceutical effectiveness	Engelhart et al. (2021)		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	pharmaceutical effectiveness	Engelhart et al. (2021)	'E484K'	Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	pharmaceutical effectiveness	Engelhart et al. (2021)	'K417T', 'E484K'	Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from P.1.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	pharmaceutical effectiveness	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	pharmaceutical effectiveness	Liu et al. (2021)		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	reinfection	Malta Romano et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	syncytium formation	Kim et al. (2021)	'D614G'	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	syncytium formation	Kim et al. (2021)	'E484K', 'D614G'	~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	trafficking	Esclera et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	trafficking	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	trafficking	Kim et al. (2021)	'D614G'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	trafficking	Kim et al. (2021)	'D614G'	~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	trafficking	Kim et al. (2021)	'E484K', 'D614G'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	trafficking	Kim et al. (2021)	'E484K', 'D614G'	~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	200	100						0	200	A	T	P.1, P.1	trafficking	Kuzmina et al. (2021)	'D614G'	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	True, True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	trafficking	Kuzmina et al. (2021)	'E484K', 'D614G'	~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	trafficking	Motozono et al. (2021)		Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	trafficking	Tada et al. (2021)		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully]	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	transmissibility	Stefanelli et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'D614G', 'H655Y'	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Alenquer et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Andrade et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Bates et al. (2021)		Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Chen et al. (2021)	'E484K'	The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Choi et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Edara et al. (2021)		1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay. 	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Gallagher et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Gong et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Hitchlings et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Jacobson et al. (2021)		The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Kuzmina et al. (2021)	'D614G'	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Kuzmina et al. (2021)	'E484K', 'D614G'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Leier et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Rathnasinghe et al. (2021)		Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Tarke et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Wang et al. (2021)		In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccine neutralization efficacy	Xie et al. (2021)	'E484K'	In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G'	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	virion structure	Spratt et al. (2021)		Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type) 	False	True	Gamma	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	100	100						0	100	A	T	P.1	virion structure	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	True	Gamma	VOC		11-Jan-2021	
p.P2018P	c.A6054G	p.P2018P			6319	orf1ab	ORF1ab	SILENT	100	100			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	100	A	G	P.1					False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.58x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	anthropozoonotic events	Montagutelli et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	antibody epitope effects	Chen et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	antibody epitope effects	Dejnirattisai et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S'	"The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (~wild type), with only 64% neutralization at 10 μg/mL.  Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed.  Given that there is likely a single supersite (""i"") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primaruly anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with  neutralization of Victoria (~wild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1,  with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a  greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351."	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	antibody epitope effects	Wang et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G'	1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Hoffman et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Luftig et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	McCallum et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Mendes-Correa et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Tang et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Wang et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	pharmaceutical effectiveness	Hoffman et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	reinfection	Malta Romano et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	trafficking	Esclera et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	trafficking	Hoffman et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	transmissibility	Stefanelli et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y'	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Alenquer et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Andrade et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Chen et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Choi et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Gallagher et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Gong et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Hitchlings et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Hoffman et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Leier et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Tarke et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Wang et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G'	1.23x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	100	100						0	100	C	T	P.1	virion structure	Wang et al. (2021)	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	True	Gamma	VOC		11-Jan-2021	
p.P4715L	c.C14144T	p.P4715L			14408	orf1ab	ORF1ab	MISSENSE	100	100			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	100	C	T	P.1					False	True	Gamma	VOC		11-Jan-2021	
p.P80R	c.C239G	p.P80R			28512	N	N	MISSENSE	100	100						0	100	C	G	P.1					False	True	Gamma	VOC		11-Jan-2021	
p.P959S	c.C2875T	p.P959S			3140	orf1ab	ORF1ab	MISSENSE	100	100			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	89	11	C	T	P.1					False	False	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.82x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	anthropozoonotic events	Montagutelli et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	antibody epitope effects	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	antibody epitope effects	Dejnirattisai et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y'	"The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (~wild type), with only 64% neutralization at 10 μg/mL.  Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed.  Given that there is likely a single supersite (""i"") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primaruly anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with  neutralization of Victoria (~wild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1,  with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a  greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351."	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	antibody epitope effects	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G'	1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	convalescent plasma escape	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	convalescent plasma escape	Luftig et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	convalescent plasma escape	McCallum et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	convalescent plasma escape	Mendes-Correa et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	convalescent plasma escape	Tang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	convalescent plasma escape	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	pharmaceutical effectiveness	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	reinfection	Malta Romano et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	trafficking	Esclera et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	trafficking	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	transmissibility	Stefanelli et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'E484K', 'N501Y', 'D614G', 'H655Y'	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	vaccine neutralization efficacy	Alenquer et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	vaccine neutralization efficacy	Andrade et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	vaccine neutralization efficacy	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	vaccine neutralization efficacy	Choi et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	vaccine neutralization efficacy	Gallagher et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	vaccine neutralization efficacy	Gong et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	vaccine neutralization efficacy	Hitchlings et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	vaccine neutralization efficacy	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	vaccine neutralization efficacy	Leier et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	vaccine neutralization efficacy	Tarke et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	vaccine neutralization efficacy	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G'	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.59x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	virion structure	Spratt et al. (2021)		Estimated free energy change (ddG) for this variant is -0.69 kcal/mol (i.e. destabilizing relative to wild type) 	False	True	Gamma	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	99	100						0	99	G	T	P.1	virion structure	Wang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	True	Gamma	VOC		11-Jan-2021	
p.RG203KR	c.AGTAGGG604_610TCTAAAC	p.RG203KR			28877	N	N		100	100						0	100	AGTAGGG	TCTAAAC	P.1					False	True	Gamma	VOC		11-Jan-2021	
p.S1188L	c.C3563T	p.S1188L			3828	orf1ab	ORF1ab	MISSENSE	100	100			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	100	C	T	P.1					False	True	Gamma	VOC		11-Jan-2021	
p.S253P	c.T757C	p.S253P			26149	ORF3a	ORF3a	MISSENSE	100	100						0	100	T	C	P.1					False	True	Gamma	VOC		11-Jan-2021	
p.S3675del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'3676del', 'F3677del'	11287	orf1ab	ORF1ab		100	100			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	100	GTCTGGTTTT	G	P.1					False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.69x decrease in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	anthropozoonotic events	Montagutelli et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	antibody epitope effects	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G'	1.56x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Luftig et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	McCallum et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Mendes-Correa et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	convalescent plasma escape	Tang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	pharmaceutical effectiveness	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	reinfection	Malta Romano et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	trafficking	Esclera et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	trafficking	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Alenquer et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Andrade et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Choi et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Gallagher et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Gong et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Hitchlings et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Leier et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccine neutralization efficacy	Tarke et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G'	1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	100	100						0	100	C	T	P.1	virion structure	Spratt et al. (2021)		Estimated free energy change (ddG) for this variant is 1.51 kcal/mol (i.e. stabilizing relative to wild type) 	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.96x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G', 'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	anthropozoonotic events	Montagutelli et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	antibody epitope effects	Chen et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	antibody epitope effects	Dejnirattisai et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S'	"The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (~wild type), with only 64% neutralization at 10 μg/mL.  Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed.  Given that there is likely a single supersite (""i"") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primaruly anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with  neutralization of Victoria (~wild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1,  with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a  greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351."	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	antibody epitope effects	Wang et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	convalescent plasma binding	Gong et al. (2021)	'D614G', 'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	convalescent plasma escape	Hoffman et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	convalescent plasma escape	Luftig et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	convalescent plasma escape	McCallum et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	convalescent plasma escape	Mendes-Correa et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	convalescent plasma escape	Tang et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	convalescent plasma escape	Wang et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	pharmaceutical effectiveness	Hoffman et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	reinfection	Malta Romano et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	trafficking	Esclera et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	trafficking	Hoffman et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	transmissibility	Stefanelli et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y'	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	vaccine neutralization efficacy	Alenquer et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	vaccine neutralization efficacy	Andrade et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	vaccine neutralization efficacy	Chen et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	vaccine neutralization efficacy	Choi et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	vaccine neutralization efficacy	Gallagher et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	vaccine neutralization efficacy	Gong et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	vaccine neutralization efficacy	Hitchlings et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	vaccine neutralization efficacy	Hoffman et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	vaccine neutralization efficacy	Leier et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	vaccine neutralization efficacy	Tarke et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	vaccine neutralization efficacy	Wang et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G'	1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.39x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	vaccinee plasma binding	Gong et al. (2021)	'D614G', 'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Gamma	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	100	100						0	100	C	A	P.1	virion structure	Wang et al. (2021)	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	anthropozoonotic events	Montagutelli et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	antibody epitope effects	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	convalescent plasma escape	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	convalescent plasma escape	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	convalescent plasma escape	Luftig et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	convalescent plasma escape	McCallum et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	convalescent plasma escape	Mendes-Correa et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	convalescent plasma escape	Tang et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	pharmaceutical effectiveness	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	trafficking	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Chen et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Choi et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Gallagher et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	'E484K', 'D614G'	Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose)  and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Gong et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Hoffman et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Leier et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	True	Gamma	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	100	100						0	100	G	T	P.1	vaccine neutralization efficacy	Tarke et al. (2021)	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	True	Gamma	VOC		11-Jan-2021	
p.V2116V	c.A6348G	p.V2116V			6613	orf1ab	ORF1ab	SILENT	100	100			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	100	A	G	P.1					False	True	Gamma	VOC		11-Jan-2021	
p.Y4171Y	c.C12513T	p.Y4171Y			12778	orf1ab	ORF1ab	SILENT	200	100			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab	YP_009725305.1	0	200	C	T	P.1, P.1					False	True, True	Gamma	VOC		11-Jan-2021	
